This study is for patients who experience 15 or more headache days per month and prefer an alternative to pills or injections. The Tx360 is a nasal application device with a small, soft catheter that is placed into the nose in order to spray a small amount of FDA approved medication onto a pain nerve bundle called the SPG. The SPG is located between the nose and brain and its activation has been found to be associated with migraines.
This is a short, 3 visit study that is placebo-controlled. The study looks at a CGRP antagonist in a nasal spray formulation that may be used for the acute treatment of migraine. Participants that may qualify have 2-8 migraines per month and do not receive current treatment with a CGRP monoclonal antibody. Participants will be compensated for their time.
This study is placebo-controlled and looks at a once monthly treatment in those who are currently employed to evaluate the treatment's effect on work productivity. Those who suffer from migraine 4-14 days per month who have failed 1-2 preventative treatments in the past may qualify for this study. Participants cannot currently or in the past have taken a CGRP monoclonal antibody for the treatment of migraine. The study is just over a year long and participants will receive compensation for their time.
Check back in 2021 to see what new studies our site will be starting! We will have both acute and preventative migraine treatment studies. Keep your eyes open for more details on these new studies!